Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Splenomegaly

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    239 result(s) found for: Splenomegaly. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-000861-58 Sponsor Protocol Number: NP39761 Start Date*: 2019-10-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IDASANUTLIN MONOTHERAPY IN PARTICIPANTS WITH HYDROXYUREA-RESISTANT/INTOLERANT POL...
    Medical condition: Polycythemia Vera (PV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001671-21 Sponsor Protocol Number: KRT-232-101 Start Date*: 2018-10-03
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed P...
    Medical condition: Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF(Post–ET-MF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) CZ (Ongoing) HU (Ongoing) ES (Ongoing) PL (Ongoing) BG (Ongoing) LT (Ongoing) IT (Ongoing) PT (Ongoing) HR (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001672-38 Sponsor Protocol Number: KRT-232-102 Start Date*: 2018-12-10
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemi...
    Medical condition: Phlebotomy-dependent polycythemia vera. Polycythemia Vera (PV) is classified as a myeloproliferative neoplasm (MPN).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Prematurely Ended) ES (Ongoing) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002567-42 Sponsor Protocol Number: 5A Start Date*: 2015-07-15
    Sponsor Name:Stockholm County Council, Karolinska University Hospital Huddinge, Dept of Anesthesiology and Intensive Care
    Full Title: Predictors of albumin synthesis rate in severe liver failure. An open exploratory study in patients with chronic liver failure assessed for liver transplantation
    Medical condition: Severe chronic liver failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004928-21 Sponsor Protocol Number: CINC424A2353 Start Date*: 2016-01-27
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A randomized, double blind, placebo-controlled, multi-center, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations
    Medical condition: Early Myelofibrosis patients with high molecular risk mutations
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) HU (Completed) GR (Completed) FR (Prematurely Ended) PT (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000557-27 Sponsor Protocol Number: M20-178 Start Date*: 2020-09-14
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis...
    Medical condition: Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Ongoing) BE (Completed) SE (Ongoing) PL (Ongoing) GR (Ongoing) AT (Ongoing) DK (Ongoing) IT (Ongoing) BG (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002391-17 Sponsor Protocol Number: HLH-2004 Start Date*: 2005-03-10
    Sponsor Name:AZIENDA DI RILIEVO NAZIONALE E DI ALTA SPECIALIZZAZIONE OSPEDALE CIVICO E BENFRATELLI, G.DI CRISTINA E M.ASCOLI
    Full Title: Treatment protocol of the second international study for hemophagoocytic lymphohistiocytosis (HLH)
    Medical condition: Hemophagocytic lymphohistiocytosis (HLH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049646 Lymphohistiocytosis PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002132-25 Sponsor Protocol Number: 12-181 Start Date*: 2015-06-29
    Sponsor Name:University Hospital Aachen AöR, represented by the executive board, represented by the Dean of the Medical Faculty
    Full Title: RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial
    Medical condition: Myeloproliferative Neoplasms (MPN): high-risk Polycythemia Vera (PV) and high-risk Essential Thrombocythemia (ET)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000498-42 Sponsor Protocol Number: PB-06-001 Start Date*: 2008-05-08
    Sponsor Name:Protalix Biotherapeutics
    Full Title: A Phase III Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patient...
    Medical condition: Gaucher disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018048 Gaucher's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002707-33 Sponsor Protocol Number: GS-US-352-0101 Start Date*: 2014-05-27
    Sponsor Name:Sierra Oncology, Inc.
    Full Title: A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thromboc...
    Medical condition: Primary Myleofibrosis (PMF) or post-Polycythemia vera or post-Essential Thrombocythemia Myelofibrosis (post-PV/ET MF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) BE (Completed) GB (Completed) AT (Completed) SE (Completed) ES (Completed) HU (Completed) NL (Completed) DK (Completed) BG (Completed) RO (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001897-25 Sponsor Protocol Number: EFC12153 Start Date*: 2011-12-21
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibros...
    Medical condition: Primary myelofibrosis, post-polycythemia vera myelofibrosis, or post- essential thrombocythemia myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10018864 Haematopoietic neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) LT (Completed) PT (Prematurely Ended) ES (Prematurely Ended) DE (Completed) SE (Prematurely Ended) AT (Completed) IT (Completed) CZ (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005066-38 Sponsor Protocol Number: CINC424AGB02 Start Date*: 2012-03-09
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A UK open-label, multicentre, exploratory Phase II study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelof...
    Medical condition: primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV MF) or Post essential thrombocythemia myelofibrosis (PET-MF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005279-18 Sponsor Protocol Number: RG_11-164 Start Date*: 2012-02-08
    Sponsor Name:University of Birmingham
    Full Title: A RandoMised study of best Available therapy versus JAK Inhibition in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide.
    Medical condition: Polycythaemia vera Essential Thrombocythaemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-001569-33 Sponsor Protocol Number: LLC-R-FCM-1 Start Date*: 2005-09-23
    Sponsor Name:Dept. Hematology, Hospital Clinic
    Full Title: First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamie...
    Medical condition: Patients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treated
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004150-13 Sponsor Protocol Number: 30032016 Start Date*: 2018-12-20
    Sponsor Name:Zealand University hospital
    Full Title: Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy Study.
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000741-19 Sponsor Protocol Number: Fl SC ale (Full-Scale) Start Date*: 2007-07-04
    Sponsor Name:UHL NHS Trust
    Full Title: A phase I study of subcutaneous alemtuzumab in combination with oral fludarabine in previously untreated patients with chronic lymphocytic leukaemia.
    Medical condition: Chronic Lymphocytic Leukaemia (CLL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004824-19 Sponsor Protocol Number: ML21206 Start Date*: 2008-08-08
    Sponsor Name:Roche Austria GmbH
    Full Title: Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study
    Medical condition: Chronic Lymphocytic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002318-37 Sponsor Protocol Number: INCB18424-357 Start Date*: 2012-11-06
    Sponsor Name:Incyte Corporation
    Full Title: Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
    Medical condition: Polycythemia Vera
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) ES (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005222-37 Sponsor Protocol Number: GZGD02507 Start Date*: 2009-11-04
    Sponsor Name:Genzyme Europe B.V.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1
    Medical condition: Gaucher Disease type I
    Disease: Version SOC Term Classification Code Term Level
    13.1 10010331 - Congenital, familial and genetic disorders 10018048 Gaucher's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-002840-21 Sponsor Protocol Number: HGT-GCB-039 Start Date*: 2007-10-30
    Sponsor Name:Shire Human Genetic Therapies Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared with Imiglucerase in Patients with Type I Gauc...
    Medical condition: Type I Gaucher disease Enfermedad de Gaucher tipo 1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018048 Gaucher's disease LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:19:41 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA